Evidence map›Paper›PMID 32751706›Full record

ReviewInternational journal of molecular sciences2020

Immune-Checkpoint Blockade Therapy in Lymphoma.

Ayumi Kuzume, SungGi Chi, Nobuhiko Yamauchi, Yosuke Minami

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. The Application of PD-1 Inhibitors in Immunotherapy for Glioblastoma.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Hepatocellular carcinoma: signaling pathways and therapeutic advances.Signal transduction and targeted therapy · 2025
    Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Ayumi KuzumeDepartment of Hematology, National Cancer Center Hospital East, Kashiwa 277-8577, Japan.
SungGi ChiDepartment of Hematology, National Cancer Center Hospital East, Kashiwa 277-8577, Japan.ORCID 0000-0002-5725-7187
Nobuhiko YamauchiDepartment of Hematology, National Cancer Center Hospital East, Kashiwa 277-8577, Japan.
Yosuke MinamiDepartment of Hematology, National Cancer Center Hospital East, Kashiwa 277-8577, Japan.
National Cancer Center Hospital East · JPKameda Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor cells use immune-checkpoint pathways to evade the host immune system and suppress immune cell function. These cells express programmed cell-death protein 1 ligand 1 (PD-L1)/PD-L2, which bind to the programmed cell-death protein 1 (PD-1) present on cytotoxic T cells, trigger inhibitory signaling, and reduce cytotoxicity and T-cell exhaustion. Immune-checkpoint blockade can inhibit this signal and may serve as an effective therapeutic strategy in patients with solid tumors. Several trials have been conducted on immune-checkpoint inhibitor therapy in patients with malignant lymphoma and their efficacy has been reported. For example, in Hodgkin lymphoma, immune-checkpoint blockade has resulted in response rates of 65% to 75%. However, in non-Hodgkin lymphoma, the response rate to immune-checkpoint blockade was lower. In this review, we evaluate the biology of immune-checkpoint inhibition and the current data on its efficacy in malignant lymphoma, and identify the cases in which the treatment was more effective.

Indexed as

Antibodies, MonoclonalB7-H1 AntigenCTLA-4 AntigenHumansImmune Checkpoint InhibitorsImmunotherapyLymphomaProgrammed Cell Death 1 ReceptorAntibodies, MonoclonalB7-H1 AntigenCD274 protein, humanCTLA-4 AntigenImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 Receptorhematologic malignanciesimmunotherapyprogrammed cell-death protein 1 (PD-1)

Identifiers

PMID32751706
PMCPMC7432396
OpenAlexW3046053699

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.